70 related articles for article (PubMed ID: 25265435)
21. [Detection of t (14; 18) translocation and bcl-2 amplification in diffuse large B-cell lymphoma].
Jiang HY; Li HL; Hu H; He Y; Zhao T
Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):84-9. PubMed ID: 17493380
[TBL] [Abstract][Full Text] [Related]
22. [Expression of miR-224 in diffuse large B cell lymphoma and its clinical significance].
Song G; Gu L; He B; Pan Y; Wang S
Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):619-22. PubMed ID: 25052605
[TBL] [Abstract][Full Text] [Related]
23. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
Choi JW; Kim Y; Lee JH; Kim YS
Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
[TBL] [Abstract][Full Text] [Related]
24. [Analysis of bcl-6 protein expression and gene rearrangement in diffuse large B-cell lymphoma].
Min DL; Xia HL; Zhou XY; Sun MH; Yang WT; Zhang TM; Zheng AH; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2005 Jun; 34(6):327-31. PubMed ID: 16185497
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological features of HCV-positive splenic diffuse large B cell lymphoma.
Shimono J; Miyoshi H; Arakawa F; Yamada K; Sugio T; Miyawaki K; Eto T; Miyagishima T; Kato K; Nagafuji K; Akashi K; Teshima T; Ohshima K
Ann Hematol; 2019 May; 98(5):1197-1207. PubMed ID: 30729289
[TBL] [Abstract][Full Text] [Related]
26. The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma.
Ruminy P; Etancelin P; Couronné L; Parmentier F; Rainville V; Mareschal S; Bohers E; Burgot C; Cornic M; Bertrand P; Lenormand B; Picquenot JM; Jardin F; Tilly H; Bastard C
Leukemia; 2011 Apr; 25(4):681-8. PubMed ID: 21233831
[TBL] [Abstract][Full Text] [Related]
27. [Mechanism and clinical significance of anti-apoptotic gene bcl-2 expression in diffuse large B-cell lymphoma].
Zeng LP; Wen YL; Ma Y; Wang GQ; Li Y; Wang J; Xu LL; Zhang XM
Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):377-81. PubMed ID: 21914345
[TBL] [Abstract][Full Text] [Related]
28. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ
Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767
[TBL] [Abstract][Full Text] [Related]
29. Tissue microarrays in diffuse large B-cell lymphomas: are they really able to identify distinct prognostic groups in lymphomas of both nodal and extranodal origin?
Laszlo D; Pruneri G; Andreola G; Radice D; Calabrese L; Rafaniello PR; Nassi L; Sammassimo S; Alietti A; Agazzi A; Vanazzi A; Martinelli G
Int J Surg Pathol; 2011 Aug; 19(4):417-24. PubMed ID: 19793830
[TBL] [Abstract][Full Text] [Related]
30. [Nodal versus extranodal diffuse large B-cell lymphoma: comparison of clinicopathologic features, immunophenotype and prognosis].
Lu JB; Li XQ; Zhang PH; Zhou XY; Zhang TM; Li XM; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):470-3. PubMed ID: 17845761
[TBL] [Abstract][Full Text] [Related]
31. Biological characterization of nodal versus extranodal presentation of diffuse large B-Cell lymphoma using immunohistochemistry.
Kim MK; Bae SH; Bae YK; Kum YS; Ryoo HM; Cho HS; Lee KH; Koh SA; Lee HY; Yun SY; Choi JH; Hyun MS
Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):403-8. PubMed ID: 21700526
[TBL] [Abstract][Full Text] [Related]
32. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma.
Alacacioglu I; Ozcan MA; Ozkal S; Piskin O; Turgut N; Demirkan F; Ozsan GH; Kargi A; Undar B
Hematology; 2009 Apr; 14(2):84-9. PubMed ID: 19298719
[TBL] [Abstract][Full Text] [Related]
34. FOXP1 protein overexpression is associated with inferior outcome in nodal diffuse large B-cell lymphomas with non-germinal centre phenotype, independent of gains and structural aberrations at 3p14.1.
Hoeller S; Schneider A; Haralambieva E; Dirnhofer S; Tzankov A
Histopathology; 2010 Jul; 57(1):73-80. PubMed ID: 20579129
[TBL] [Abstract][Full Text] [Related]
35. EBV-miR-BHRF1-2 targets PRDM1/Blimp1: potential role in EBV lymphomagenesis.
Ma J; Nie K; Redmond D; Liu Y; Elemento O; Knowles DM; Tam W
Leukemia; 2016 Mar; 30(3):594-604. PubMed ID: 26530011
[TBL] [Abstract][Full Text] [Related]
36. Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay.
Kim SJ; Sohn I; Do IG; Jung SH; Ko YH; Yoo HY; Paik S; Kim WS
Ann Hematol; 2014 Mar; 93(3):437-47. PubMed ID: 23975159
[TBL] [Abstract][Full Text] [Related]
37. c-FLIP does not correlate with response to immunochemotherapy treatment and outcome of patients with nodal diffuse large B-cell lymphoma.
Markovic O; Marisavljevic D; Cemerikic-Martinovic V; Filipovic B; Radovanović S; Zdravković M; Stanisavljevic D; Mihaljevic B
Biomed Pharmacother; 2013 Jun; 67(5):445-9. PubMed ID: 23582793
[TBL] [Abstract][Full Text] [Related]
38. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma.
Lawrie CH; Gal S; Dunlop HM; Pushkaran B; Liggins AP; Pulford K; Banham AH; Pezzella F; Boultwood J; Wainscoat JS; Hatton CS; Harris AL
Br J Haematol; 2008 May; 141(5):672-5. PubMed ID: 18318758
[TBL] [Abstract][Full Text] [Related]
39. Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces.
Sangaletti S; Iannelli F; Zanardi F; Cancila V; Portararo P; Botti L; Vacca D; Chiodoni C; Di Napoli A; Valenti C; Rizzello C; Vegliante MC; Pisati F; Gulino A; Ponzoni M; Colombo MP; Tripodo C
EBioMedicine; 2020 Nov; 61():103055. PubMed ID: 33096480
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of aberrant microRNAs expression in predicting disease relapse/refractoriness to treatment in diffuse large B-cell lymphoma: A meta-analysis.
Ting CY; Liew SM; Price A; Gan GG; Bee-Lan Ong D; Tan SY; Bee PC
Crit Rev Oncol Hematol; 2019 Dec; 144():102818. PubMed ID: 31733445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
